Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1303-7372 | Other Identifier | World Health Organization (WHO) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will help to better understand the course of disease in people with haemophilia (A or B [with or without inhibitors]) and the haemophilia care scenario in the selected countries and the experience so far in dealing with the condition. This is a survey-based study; hence no medications or other treatments will be provided to participants as a part of this study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experienced/Senior Treating Physicians | This group includes haematologists, paediatric haematologist and physicians treating patients with haemophilia (PWH) |
| |
| Patients Organisations | This group includes the organisations working closely to support patient with haemophillia (PWH) at a national/regional level |
| |
| Patients/Caregivers | This group includes patients with haemophilia and caregivers managing patients with haemophilia |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No treatment given | Other | No treatment given |
|
| Measure | Description | Time Frame |
|---|---|---|
| Estimated prevalence of haemophilia | Proportion [%] of individuals in a population | From start of data collection to end of data collection (approximately 5 months) |
| Estimated incidence of haemophilia | Number of new cases of haemophilia | From start of data collection to end of data collection (approximately 5 months) |
| Estimated proportion of patients with haemophilia (PWH) who develop inhibitors (%) | proportion [%] of individuals in a population | From start of data collection to end of data collection (approximately 5 months) |
Not provided
Not provided
Inclusion Criteria:
For Experienced/Senior Treating Physicians
Experienced/senior haematologist treating haemophilia (adult or paediatric) or physician treating patients with haemophilia. (PWH), with greater than 5 years of experience.
Able to communicate in English or country specific language.
Agree/sign informed consent before data collection. For Patients Organisations
Patient organisation supporting haemophilia.
Expert having greater than 3 years of work experience with the patient organisation.
Expert level understanding of haemophilia landscape and care pathway in the relevant country.
Able to communicate in English or country specific language.
Agree/sign informed consent before data collection. For Patients/Caregivers
Patients of all age groups, diagnosed with haemophilia A or haemophilia B (with or without inhibitors) for greater than 2 years.
For patients less than 18 years of age (*less than 19 years for South Korea), their caregivers aged greater than or equal to 18 years (*greater than or equal to19 years for South Korea) should sign the informed consent.
*For South Korea, the adult age is 19 years.
Able to communicate in English or country specific language.
Agree/sign informed consent before data collection.
Exclusion Criteria:
There is no explicit exclusion criterion in this study, thus any participants group who answers "no" to any of the inclusion criteria will be excluded from the study.
Not provided
Not provided
Not provided
Not provided
Not provided
The study will enroll 3 types of participant categories:
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Transparency (dept. 2834) | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novo Nordisk Investigational Site | Bangalore | Karnataka | 560 066 | India | ||
| Novo Nordisk Investigational Site |
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006467 | Hemophilia A |
| ID | Term |
|---|---|
| D025861 | Blood Coagulation Disorders, Inherited |
| D001778 | Blood Coagulation Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Kuala Lumpur |
| 50470 |
| Malaysia |
| Novo Nordisk Investigational Site | Seoul | South Korea |
| Novo Nordisk Investigational Site | Bangkok | 10500 | Thailand |
| D020147 | Coagulation Protein Disorders |
| D006474 | Hemorrhagic Disorders |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |